-
Recent Posts
- Digital Technology for Early Detection of Neurodegenerative Disease (BBC News / EDoN)
- NICE Guideline on Support for Adult Carers (NICE)
- Flavonols Re-Visited (Neurology / NHS Digital – Behind the Headlines / Bazian)
- Summary of NICE’s Impact on Dementia Health and Care (NICE)
- Dementia and Housing: Updated (SCIE)
Archives
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Value Based Pricing
Fair and Affordable Access to Medicines in the NHS (NHS England / UCL IIPP)
Summary Adalimumab is a medicine on which hospitals spend more than £400 million a year. The patent has now expired, allowing patients to be treated with a cheaper biosimilar, saving around £150 million per year (which can be re-directed to … Continue reading →
Posted in Acute Hospitals, Commissioning, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, National, NHS, NHS England, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Access to Medicines, Adalimumab, Added Benefit of New Drugs (Analysis), Affordability, Affordability (Facilitators of Innovation), Affordability and Access to Essential Medicines, Affordable Medicines, Alignment of Corporate Interests With the Public Interest, Alternative Health Innovation Model (Proposals), Andrew Davies: Director of Hospital Pharmacy at NHS Improvement, Association of the British Pharmaceutical Industry (ABPI), Barriers to Collaboration and Knowledge Sharing, Barriers to Innovation, Barriers to Innovation: Dominance of Vested Interests, Better Procurement, BioCubaFarma, Biological Medicines and Biosimilars, Biosimilars for Adalimumab, Cancer Innovation Fund (CIF), Charging Prices the Market Will Bear, Collaboration and Transparency, Compulsory Licensing, Compulsory or Public Non-Commercial Use Licences, Decline of Drugs Research and Development Efficiency, Defense Advanced Research Projects Agency (Darpa), Delinkage, Delinkage of Incentives for Innovation From High Prices, Directed Innovation, Direction of Innovation for Public Value, Drug Patent Monopolies: Negation of Competition, Drug Patents, Drug Pricing Negotiations, Drug Pricing Strategies, Drugs for Neglected Diseases initiative (DNDi), Effective Knowledge Sharing, Energiewende in Germany, European Public Health Alliance, Expensive Drugs, Finance and Budgeting: Affordability (Barriers to Innovation), Finance and Procurement, Global Justice Now, Health Advanced Research Projects Agency (HARPA), Health Innovation, Health Innovation Better Managed to Deliver Public Value, Heidi Chow: Global Justice Now, High Medication Prices Placing Pressure on NHS Budgets and Causing Rationing, High Prices Failing to Reflect Social Value, Highly-Priced Medicines, Human Genome Project (HGP), I-MAK, Improving Access to Medicines, Incentivising Investment in Innovation, Inefficiencies in Innovation, Innogen, Innovation and Improvement, Innovation Direction, Intellectual Property Rights (IPR) Geared to Encouraging Innovation, Intellectual Property Rights (IPR) Geared to Public Value, Intellectual Property Rules Geared for Public Health, International Nonproprietary Names (INN), Just Treatment, Knowledge Ecology International, Knowledge Governance, Lack of Safeguards in Current Pharma R&D Model, Lack of Transparency and Public Accountability, Lack of Transparency and Stifled Collaboration, Learning from DARPA, Mariana Mazzucato: UCL Institute for Innovation and Public Purpose, Me-Too Drugs, Medicines Patent Pool (MPP), Medicines Price Transparency, Mission-Driven Innovation, Mission-Oriented Innovation Policy, Mission-Oriented Thinking, Monopoly Pricing, Open Society Foundations, Opportunities for Volume-Based and Pooled Procurement, Out-of-Reach Drug Prices, Patent Monopolies Negating Competition, Patentability Criteria Consistent With TRIPS Agreement, Patents Blocking Learning Diffusion and Collaboration, People’s Prescription: Re-Imagining Health Innovation to Deliver Public Value, Pharmaceutical Price Regulation Scheme (PPRS), Pooled Procurement Mechanism, Pricing Legislation, Principles of Health Innovation Model Designed For Public Value, Procurement, Profit Maximisation Versus Public Value Maximisation, Public Investment in Biomedical Innovation, Public Purpose, Public Purpose and Public Value, Public Value, Public Value Maximisation, Reducing Spending on Expensive Drugs, Reducing Waste in the NHS, Saoirse Fitzpatrick: STOPAIDS, Short-Termism and Financialisation, Simon Stevens: Chief Executive of NHS England, Smart Procurement, Social Value, STOPAIDS, Thinking Like a Patient and Acting Like a Taxpayer, Trade Related Aspects of Intellectual Property Rights (TRIPS), TRIPS Agreement, TRIPs-Plus Provisions, Upstream Investment in Research and Development Negotiated Into Better Downstream Public Benefit, US Biochemical Advanced Research and Development Authority (BARDA), US Department of Health: Health Advanced Research Projects Agency (HARPA), Value Based Pricing, Value-Based Pricing (Imperfect Model), Value-Based Pricing: Corrupted Into Maximising Value Extraction (Versus Public Good), Variations in Procurement, Voluntary Scheme for Branded Medicines Pricing and Access, World Intellectual Property Organisation (WIPO)
|
Leave a comment
